In addition, in a murine model of thyroid cancer, it has been demonstrated that targeting TAMs trough inhibition of CSF-1/CSF-1R impairs BRAFV600E-induced thyroid cancer progression [16]. Here, CSF1 is linked to thyroid cancer.